New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin;   - film coated tablet - 10 mg - active: atorvastatin calcium 10.85mg equivalent to 10 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 21.7mg equivalent to 20 mg atorvastatin;   - film coated tablet - 20 mg - active: atorvastatin calcium 21.7mg equivalent to 20 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 43.4mg equivalent to 40 mg atorvastatin;   - film coated tablet - 40 mg - active: atorvastatin calcium 43.4mg equivalent to 40 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

upjohn new zealand ulc - atorvastatin calcium 86.8mg equivalent to 80 mg atorvastatin;   - film coated tablet - 80 mg - active: atorvastatin calcium 86.8mg equivalent to 80 mg atorvastatin   excipient: calcium carbonate croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-7040 polysorbate 80 simeticone - atorvastatin pfizer is indicated as an adjunct to diet to reduce elevated total-c, ldl-c and tg levels in patients with primary hypercholesterolaemia or mixed dyslipidaemia where the primary abnormality is either elevated cholesterol or triglycerides when response to diet and other non-pharmacological measures is inadequate. atorvastatin pfizer is also indicated to reduce total-c and ldl-c in patients with heterozygous and homozygous familial hypercholesterolaemia.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer ireland pharmaceuticals - atorvastatin calcium - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer ireland pharmaceuticals - atorvastatin calcium - film-coated tablet - 80 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer ireland pharmaceuticals - atorvastatin calcium - film-coated tablet - 10 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer ireland pharmaceuticals - atorvastatin calcium - film-coated tablet - 20 milligram(s) - hmg coa reductase inhibitors; atorvastatin

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - atorvastatin calcium -

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 5 mg - amlodipine and benazepril hydrochloride capsules, usp are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. - do not coadminister aliskiren with angiotensin receptor blockers (arbs), ace inhibitors, including amlodipine and benazepril hydrochloride in patients with diabetes. - amlodipine and benazepril hydrochloride is contraindicated in patients with a history of angioedema, with or without previous ace inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ace inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules. - amlodipine and benazepril hydrochloride is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan